Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes

Hoppes, R. et al. (2014) Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes. Journal of Immunology, 193(10), pp. 4803-4813. (doi: 10.4049/jimmunol.1400800) (PMID:25311806) (PMCID:PMC4226423)

Full text not currently available from Enlighten.


Virus or tumor Ag–derived peptides that are displayed by MHC class I molecules are attractive starting points for vaccine development because they induce strong protective and therapeutic cytotoxic T cell responses. In thus study, we show that the MHC binding and consequent T cell reactivity against several HLA-A*02 restricted epitopes can be further improved through the incorporation of nonproteogenic amino acids at primary and secondary anchor positions. We screened more than 90 nonproteogenic, synthetic amino acids through a range of epitopes and tested more than 3000 chemically enhanced altered peptide ligands (CPLs) for binding affinity to HLA-A*0201. With this approach, we designed CPLs of viral epitopes, of melanoma-associated Ags, and of the minor histocompatibility Ag UTA2-1, which is currently being evaluated for its antileukemic activity in clinical dendritic cell vaccination trials. The crystal structure of one of the CPLs in complex with HLA-A*0201 revealed the molecular interactions likely responsible for improved binding. The best CPLs displayed enhanced affinity for MHC, increasing MHC stability and prolonging recognition by Ag-specific T cells and, most importantly, they induced accelerated expansion of antitumor T cell frequencies in vitro and in vivo as compared with the native epitope. Eventually, we were able to construct a toolbox of preferred nonproteogenic residues with which practically any given HLA-A*02 restricted epitope can be readily optimized. These CPLs could improve the therapeutic outcome of vaccination strategies or can be used for ex vivo enrichment and faster expansion of Ag-specific T cells for transfer into patients.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Rodenko, Dr Boris
Authors: Hoppes, R., Oostvogels, R., Luimstra, J. J., Wals, K., Toebes, M., Bies, L., Ekkebus, R., Rijal, P., Celie, P. H.N., Huang, J. H., Emmelot, M. E., Spaapen, R. M., Lokhorst, H., Schumacher, T. N.M., Mutis, T., Rodenko, B., and Ovaa, H.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Journal of Immunology
Publisher:American Association of Immunologists
ISSN (Online):1550-6606
Copyright Holders:Copyright © 2014 The American Association of Immunologists, Inc.
First Published:First published in Journal of Immunology 193(10):4803-1813
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record